FCMI
VYGR icon

Foresite Capital Management IV’s Voyager Therapeutics VYGR Stock Holding History

Foresite Capital Management IV’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-516,751
Closed -$5.51M – 15
2020
Q3 		$5.51M Hold
516,751
– – 1.24% 12
2020
Q2 		$6.52M Hold
516,751
– – 3.18% 9
2020
Q1 		$4.73M Sell
516,751
-313,814
-38% -$3.6M 5.83% 6
2019
Q4 		$11.6M Hold
830,565
– – 5% 7
2019
Q3 		$14.3M Buy
830,565
+293,794
+55% +$6.17M 4.62% 9
2019
Q2 		$14.6M Buy
536,771
+358,967
+202% +$8.21M 4.13% 11
2019
Q1 		$3.4M Buy
+177,804
New +$2.32M 1.22% 14

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Foresite Capital Management IV's VYGR Position: Q4 2020 in Review

Foresite Capital Management IV sold out of Voyager Therapeutics (VYGR) in Q4 2020, closing a stake of 516,751 shares — an estimated $5.51M sold.

Foresite Capital Management IV first reported a position in VYGR in Q1 2019 and held it in 7 quarters. The position peaked at $14.6M in Q2 2019. 101 funds tracked by Wall St. Rank hold VYGR as of Q4 2020.

  • Foresite Capital Management IV reported no remaining Voyager Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 516,751 Voyager Therapeutics shares in Q4 2020, an estimated $5.51M.
  • Foresite Capital Management IV first reported a position in Voyager Therapeutics in Q1 2019 and held it in 7 quarters.
  • Foresite Capital Management IV's Voyager Therapeutics position peaked at $14.6M in Q2 2019.
  • 101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2020.

Based on Foresite Capital Management IV's 13F filing for Q4 2020, filed 16 Feb 2021.